HC Wainwright Has Optimistic Outlook of SGMT FY2030 Earnings

Posted by on May 13th, 2026

Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – HC Wainwright lifted their FY2030 earnings per share estimates for Sagimet Biosciences in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $2.34 for the year, up from their prior estimate of $2.33. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.15) per share.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.06.

Other equities analysts have also recently issued reports about the stock. Barclays started coverage on shares of Sagimet Biosciences in a research report on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price target on the stock. Rodman & Renshaw initiated coverage on Sagimet Biosciences in a research note on Thursday, March 26th. They set a “buy” rating and a $28.00 price objective on the stock. Guggenheim reduced their target price on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Wall Street Zen raised Sagimet Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Canaccord Genuity Group increased their price target on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $28.63.

Read Our Latest Research Report on SGMT

Sagimet Biosciences Price Performance

Sagimet Biosciences stock opened at $7.65 on Wednesday. The company’s 50 day simple moving average is $5.94 and its 200 day simple moving average is $6.29. Sagimet Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $11.41. The firm has a market capitalization of $249.24 million, a price-to-earnings ratio of -4.87 and a beta of 3.60.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SGMT. AlphaQuest LLC acquired a new stake in Sagimet Biosciences in the 3rd quarter valued at $804,000. Landscape Capital Management L.L.C. boosted its stake in shares of Sagimet Biosciences by 14.1% during the 4th quarter. Landscape Capital Management L.L.C. now owns 25,901 shares of the company’s stock worth $153,000 after buying an additional 3,198 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Sagimet Biosciences by 31.3% in the 4th quarter. LPL Financial LLC now owns 20,574 shares of the company’s stock valued at $122,000 after acquiring an additional 4,899 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Sagimet Biosciences in the 1st quarter valued at about $105,000. Finally, Bank of America Corp DE increased its position in shares of Sagimet Biosciences by 81.8% in the second quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock valued at $76,000 after acquiring an additional 4,473 shares during the last quarter. Institutional investors own 87.86% of the company’s stock.

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

Read More

Earnings History and Estimates for Sagimet Biosciences (NASDAQ:SGMT)

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.